Written Question·Department of Health and Social Care·UIN HL1761
Breast Cancer: Drugs
Tabled: 7 July 2026
Answered: 16 July 2026
Question
To ask His Majesty's Government what estimate they have made of the number of patients who would have otherwise benefited from the HER2-low metastatic breast cancer drug Enhertu since it was rejected for use on the NHS in England in 2024.
Answer
HER2‑low breast cancer is managed with treatments for HER2‑negative breast cancer. The National Institute for Health and Care Excellence (NICE) has published guidance recommending a number of medicines for the treatment of HER2-negative breast cancer whic...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN HL1761) →